APO Research
Talk to an analyst

APO RESEARCH · REPORT

Rivaroxaban

Rivaroxaban is an oral anticoagulant invented and manufactured by Bayer; in a number of countries it is marketed as Xarelto. In the United States, it is marketed by Janssen Pharmaceutica. It is the first available orally active direct factor Xa inhibitor. Rivaroxaban is well absorbed from the gut and maximum inhibition of factor Xa occurs four hours after a dose. The effects last approximately 8–12 hours, but factor Xa activity does not return to normal within 24 hours so once-daily dosing is possible.

Explore the product
View pricing & licenses

Product & engineering

Understand the product.

Rivaroxaban is an oral anticoagulant invented and manufactured by Bayer; in a number of countries it is marketed as Xarelto. In the United States, it is marketed by Janssen Pharmaceutica. It is the first available orally active direct factor Xa inhibitor. Rivaroxaban is well absorbed from the gut and maximum inhibition of factor Xa occurs four hours after a dose. The effects last approximately 8–12 hours, but factor Xa activity does not return to normal within 24 hours so once-daily dosing is possible.

Selected research

Industry Growth & Trends

Global Rivaroxaban Industry Growth and Trends Forecast to 2032

1 January 202670 pages

Choose your research edition.

Industry ResearchRivaroxaban Industry Research Report 2026113 pages · $2,950 USDIndustry Growth & TrendsGlobal Rivaroxaban Industry Growth and Trends Forecast to 203270 pages · $3,450 USDMarket StructureGlobal Rivaroxaban Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032177 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Rivaroxaban Market Outlook and Growth Opportunities 2026197 pages · $4,250 USDMarket Analysis & ForecastGlobal Rivaroxaban Market Analysis and Forecast 2026-2032198 pages · $4,950 USD

Market perspective

Rivaroxaban is an oral anticoagulant invented and manufactured by Bayer; in a number of countries it is marketed as Xarelto. In the United States, it is marketed by Janssen Pharmaceutica. It is the first available orally active direct factor Xa inhibitor. Rivaroxaban is well absorbed from the gut and maximum inhibition of factor Xa occurs four hours after a dose. The effects last approximately 8–12 hours, but factor Xa activity does not return to normal within 24 hours so once-daily dosing is possible.

The major players in global Prom Dresses market include Bayer, Johnson and Johnson, etc. The top 2 players occupy nearly 100% of the market. Europe is the main market, and occupies nearly 100% of the global market. 10 mg is the main type, with a share over 30%. Venous Thromboembolism (VTE) is the main application, which holds a share about 85%.

Report Scope

Read the full market overview

This report provides a structured, data-driven view of the global Rivaroxaban market, combining harmonized quantitative metrics with targeted qualitative insight to support business and growth strategy, market positioning, and capital allocation.

The Rivaroxaban market size, estimates, and forecasts are presented in terms of sales volume (M Units) and revenue (US$ million), with 2025 as the base year and historical and forecast data for 2021-2032. The report segments the global Rivaroxaban market by Type, Application, region/country, and company, provides regional market sizes at the segment level, profiles the competitive landscape and key players and their market ranks, and reviews technology trends and new product developments relevant to Rivaroxaban.

Key Companies & Market Share Insights

This section analyzes the strategies and performance of leading manufacturers in the global Rivaroxaban market, including portfolio focus, innovation and product development, mergers and acquisitions, collaborations, and geographic expansion used to sustain or enhance competitive positions. It also summarizes recent corporate developments and key financial indicators and provides global revenue, price, and sales volume data by manufacturer for 2020-2025, enabling benchmarking of scale, pricing, and market share and supporting assessment of market concentration through indicators such as CR5 and CR10.

Rivaroxaban Market by Company

Bayer

J&J

Rivaroxaban Segment by Type

2.5 mg

10 mg

15 mg

20 mg

Rivaroxaban Segment by Application

Acute Coronary Syndrome (ACS)

Venous Thromboembolism (VTE)

Rivaroxaban Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Rivaroxaban market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Rivaroxaban and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Rivaroxaban.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the study scope of this report, executive summary of market segments by type, market size segments for North America, Europe, Asia Pacific, South America, Middle East & Africa.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Rivaroxaban manufacturers competitive landscape, price, sales, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.

Chapter 4: Sales, revenue of Rivaroxaban in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the future development prospects, and market space in the world.

Chapter 5: Introduces market segments by application, market size segment for North America, Europe, Asia Pacific, South America, Middle East & Africa.

Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 7, 8, 9, 10 and 11: North America, Europe, Asia Pacific, South America, Middle East & Africa, sales and revenue by country.

Chapter 12: Analysis of industrial chain, key raw materials, manufacturing cost, and market dynamics.

Chapter 13: Concluding Insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Major Company of 2.5 mg Table 2. Major Company of 10 mg Table 3. Major Company of 15 mg Table 4. Major Company of 20 mg Table 5. Global Rivaroxaban Sales by Type (2021 VS 2025 VS 2032) & (US$ Million) Table 6. Global Rivaroxaban Sales by Type (2021-2026) & (M Units) Table 7. Global Rivaroxaban Sales Market Share in Volume by Type (2021-2026) Table 8. Global Rivaroxaban Sales by Type (2021-2026) & (US$ Million) Table 9. Global Rivaroxaban Sales Market Share in Value by Type (2021-2026) Table 10. Global Rivaroxaban Price by Type (2021-2026) & (US$/Unit) Table 11. Global Rivaroxaban Sales by Type (2027-2032) & (M Units) Table 12. Global Rivaroxaban Sales Market Share in Volume by Type (2027-2032) Table 13. Global Rivaroxaban Sales by Type (2027-2032) & (US$ Million) Table 14. Global Rivaroxaban Sales Market Share in Value by Type (2027-2032) Table 15. Global Rivaroxaban Price by Type (2027-2032) & (US$/Unit) Table 16. North America Rivaroxaban Sales by Type (2021-2026) & (M Units) Table 17. North America Rivaroxaban Sales by Type (2021-2026) & (US$ Million) Table 18. Europe Rivaroxaban Sales by Type (2021-2026) & (M Units) Table 19. Europe Rivaroxaban Sales by Type (2021-2026) & (US$ Million) Table 20. Asia-Pacific Rivaroxaban Sales by Type (2021-2026) & (M Units) Table 21. Asia-Pacific Rivaroxaban Sales by Type (2021-2026) & (US$ Million) Table 22. Latin America Rivaroxaban Sales by Type (2021-2026) & (M Units) Table 23. Latin America Rivaroxaban Sales by Type (2021-2026) & (US$ Million) Table 24. Middle East and Africa Rivaroxaban Sales by Type (2021-2026) & (M Units) Table 25. Middle East and Africa Rivaroxaban Sales by Type (2021-2026) & (US$ Million) Table 26. Rivaroxaban Industry Trends Table 27. Rivaroxaban Industry Drivers Table 28. Rivaroxaban Industry Opportunities and Challenges Table 29. Rivaroxaban Industry Restraints Table 30. Global Rivaroxaban Sales Revenue by Company (US$ Million) & (2021-2026) Table 31. Global Rivaroxaban Revenue Market Share by Company (2021-2026) Table 32. Global Rivaroxaban Sales by Company (2021-2026) & (M Units) Table 33. Global Rivaroxaban Sales Share by Company (2021-2026) Table 34. Global Rivaroxaban Market Price by Company (2021-2026) & (US$/Unit) Table 35. Global Rivaroxaban Industry Company Ranking, 2024 VS 2025 VS 2026 Table 36. Global Rivaroxaban Major Company Production Sites and Headquarters Table 37. Global Rivaroxaban Company, Product Type & Application Table 38. Global Rivaroxaban Company Establishment Date Table 39. Global Company Market Concentration Ratio (CR5 and HHI) Table 40. Global Rivaroxaban by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 41. Global Rivaroxaban Market Size Comparison by Region (US$ Million): 2021 VS 2025 VS 2032 Table 42. Global Rivaroxaban Sales by Region (2021-2026) & (M Units) Table 43. Global Rivaroxaban Sales Market Share in Volume by Region (2021-2026) Table 44. Global Rivaroxaban Sales by Region (2021-2026) & (US$ Million) Table 45. Global Rivaroxaban Sales Market Share in Value by Region (2021-2026) Table 46. Global Rivaroxaban Sales (M Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 47. Global Rivaroxaban Sales by Region (2027-2032) & (M Units) Table 48. Global Rivaroxaban Sales Market Share in Volume by Region (2027-2032) Table 49. Global Rivaroxaban Sales by Region (2027-2032) & (US$ Million) Table 50. Global Rivaroxaban Sales Market Share in Value by Region (2027-2032) Table 51. Global Rivaroxaban Sales (M Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2027-2032) Table 52. Global Rivaroxaban Sales by Application (2021 VS 2025 VS 2032) & (US$ Million) Table 53. Global Rivaroxaban Sales by Application (2021-2026) & (M Units) Table 54. Global Rivaroxaban Sales Market Share in Volume by Application (2021-2026) Table 55. Global Rivaroxaban Sales by Application (2021-2026) & (US$ Million) Table 56. Global Rivaroxaban Sales Market Share in Value by Application (2021-2026) Table 57. Global Rivaroxaban Price by Application (2021-2026) & (US$/Unit) Table 58. Global Rivaroxaban Sales by Application (2027-2032) & (M Units) Table 59. Global Rivaroxaban Sales Market Share in Volume by Application (2027-2032) Table 60. Global Rivaroxaban Sales by Application (2027-2032) & (US$ Million) Table 61. Global Rivaroxaban Sales Market Share in Value by Application (2027-2032) Table 62. Global Rivaroxaban Price by Application (2027-2032) & (US$/Unit) Table 63. North America Rivaroxaban Sales by Application (2021-2026) & (M Units) Table 64. North America Rivaroxaban Sales by Application (2021-2026) & (US$ Million) Table 65. Europe Rivaroxaban Sales by Application (2021-2026) & (M Units) Table 66. Europe Rivaroxaban Sales by Application (2021-2026) & (US$ Million) Table 67. Asia-Pacific Rivaroxaban Sales by Application (2021-2026) & (M Units) Table 68. Asia-Pacific Rivaroxaban Sales by Application (2021-2026) & (US$ Million) Table 69. Latin America Rivaroxaban Sales by Application (2021-2026) & (M Units) Table 70. Latin America Rivaroxaban Sales by Application (2021-2026) & (US$ Million) Table 71. Middle East and Africa Rivaroxaban Sales by Application (2021-2026) & (M Units) Table 72. Middle East and Africa Rivaroxaban Sales by Application (2021-2026) & (US$ Million) Table 73. Bayer Company Information Table 74. Bayer Business Overview Table 75. Bayer Rivaroxaban Sales (M Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 76. Bayer Rivaroxaban Product Portfolio Table 77. Bayer Recent Development Table 78. J&J Company Information Table 79. J&J Business Overview Table 80. J&J Rivaroxaban Sales (M Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 81. J&J Rivaroxaban Product Portfolio Table 82. J&J Recent Development Table 83. North America Rivaroxaban Market Size Growth Rate (CAGR) by Country (M Units): 2021 VS 2025 VS 2032 Table 84. North America Rivaroxaban Sales by Country (2021-2026) & (M Units) Table 85. North America Rivaroxaban Sales Market Share by Country (2021-2026) Table 86. North America Rivaroxaban Sales Forecast by Country (2027-2032) & (M Units) Table 87. North America Rivaroxaban Sales Market Share Forecast by Country (2027-2032) Table 88. North America Rivaroxaban Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 89. North America Rivaroxaban Market Size by Country (2021-2026) & (US$ Million) Table 90. North America Rivaroxaban Market Share by Country (2021-2026) Table 91. North America Rivaroxaban Market Size Forecast by Country (2027-2032) & (US$ Million) Table 92. North America Rivaroxaban Market Share Forecast by Country (2027-2032) Table 93. Europe Rivaroxaban Market Size Growth Rate (CAGR) by Country (M Units): 2021 VS 2025 VS 2032 Table 94. Europe Rivaroxaban Sales by Country (2021-2026) & (M Units) Table 95. Europe Rivaroxaban Sales Market Share by Country (2021-2026) Table 96. Europe Rivaroxaban Sales Forecast by Country (2027-2032) & (M Units) Table 97. Europe Rivaroxaban Sales Market Share Forecast by Country (2027-2032) Table 98. Europe Rivaroxaban Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 99. Europe Rivaroxaban Market Size by Country (2021-2026) & (US$ Million) Table 100. Europe Rivaroxaban Market Share by Country (2021-2026) Table 101. Europe Rivaroxaban Market Size Forecast by Country (2027-2032) & (US$ Million) Table 102. Europe Rivaroxaban Market Share Forecast by Country (2027-2032) Table 103. Asia-Pacific Rivaroxaban Market Size Growth Rate (CAGR) by Country (M Units): 2021 VS 2025 VS 2032 Table 104. Asia-Pacific Rivaroxaban Sales by Country (2021-2026) & (M Units) Table 105. Asia-Pacific Rivaroxaban Sales Market Share by Country (2021-2026) Table 106. Asia-Pacific Rivaroxaban Sales Forecast by Country (2027-2032) & (M Units) Table 107. Asia-Pacific Rivaroxaban Sales Market Share Forecast by Country (2027-2032) Table 108. Asia-Pacific Rivaroxaban Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 109. Asia-Pacific Rivaroxaban Market Size by Country (2021-2026) & (US$ Million) Table 110. Asia-Pacific Rivaroxaban Market Share by Country (2021-2026) Table 111. Asia-Pacific Rivaroxaban Market Size Forecast by Country (2027-2032) & (US$ Million) Table 112. Asia-Pacific Rivaroxaban Market Share Forecast by Country (2027-2032) Table 113. Latin America Rivaroxaban Market Size Growth Rate (CAGR) by Country (M Units): 2021 VS 2025 VS 2032 Table 114. Latin America Rivaroxaban Sales by Country (2021-2026) & (M Units) Table 115. Latin America Rivaroxaban Sales Market Share by Country (2021-2026) Table 116. Latin America Rivaroxaban Sales Forecast by Country (2027-2032) & (M Units) Table 117. Latin America Rivaroxaban Sales Market Share Forecast by Country (2027-2032) Table 118. Latin America Rivaroxaban Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 119. Latin America Rivaroxaban Market Size by Country (2021-2026) & (US$ Million) Table 120. Latin America Rivaroxaban Market Share by Country (2021-2026) Table 121. Latin America Rivaroxaban Market Size Forecast by Country (2027-2032) & (US$ Million) Table 122. Latin America Rivaroxaban Market Share Forecast by Country (2027-2032) Table 123. Middle East and Africa Rivaroxaban Market Size Growth Rate (CAGR) by Country (M Units): 2021 VS 2025 VS 2032 Table 124. Middle East and Africa Rivaroxaban Sales by Country (2021-2026) & (M Units) Table 125. Middle East and Africa Rivaroxaban Sales Market Share by Country (2021-2026) Table 126. Middle East and Africa Rivaroxaban Sales Forecast by Country (2027-2032) & (M Units) Table 127. Middle East and Africa Rivaroxaban Sales Market Share Forecast by Country (2027-2032) Table 128. Middle East and Africa Rivaroxaban Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 129. Middle East and Africa Rivaroxaban Market Size by Country (2021-2026) & (US$ Million) Table 130. Middle East and Africa Rivaroxaban Market Share by Country (2021-2026) Table 131. Middle East and Africa Rivaroxaban Market Size Forecast by Country (2027-2032) & (US$ Million) Table 132. Middle East and Africa Rivaroxaban Market Share Forecast by Country (2027-2032) Table 133. Key Raw Materials Table 134. Raw Materials Key Suppliers Table 135. Rivaroxaban Distributors List Table 136. Rivaroxaban Customers List Table 137. Research Programs/Design for This Report Table 138. Authors List of This Report Table 139. Secondary Sources Table 140. Primary Sources List of Figures Figure 1. Rivaroxaban Image Figure 2. Global Rivaroxaban Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Rivaroxaban Market Size (2021-2032) & (US$ Million) Figure 4. Global Rivaroxaban Sales (2021-2032) & (M Units) Figure 5. 2.5 mg Image Figure 6. Global 2.5 mg Sales YoY Growth (2021-2032) & (M Units) Figure 7. 10 mg Image Figure 8. Global 10 mg Sales YoY Growth (2021-2032) & (M Units) Figure 9. 15 mg Image Figure 10. Global 15 mg Sales YoY Growth (2021-2032) & (M Units) Figure 11. 20 mg Image Figure 12. Global 20 mg Sales YoY Growth (2021-2032) & (M Units) Figure 13. Global Rivaroxaban Market Size Overview by Type (2021-2032) & (US$ Million) Figure 14. Global Rivaroxaban Market Share by Type 2025 VS 2032 Figure 15. North America Rivaroxaban Sales Market Share in Volume by Type in 2025 Figure 16. North America Rivaroxaban Sales Market Share in Value by Type in 2025 Figure 17. Europe Rivaroxaban Sales Market Share in Volume by Type in 2025 Figure 18. Europe Rivaroxaban Sales Market Share in Value by Type in 2025 Figure 19. Asia-Pacific Rivaroxaban Sales Market Share in Volume by Type in 2025 Figure 20. Asia-Pacific Rivaroxaban Sales Market Share in Value by Type in 2025 Figure 21. Latin America Rivaroxaban Sales Market Share in Volume by Type in 2025 Figure 22. Latin America Rivaroxaban Sales Market Share in Value by Type in 2025 Figure 23. Middle East and Africa Rivaroxaban Sales Market Share in Volume by Type in 2025 Figure 24. Middle East and Africa Rivaroxaban Sales Market Share in Value by Type in 2025 Figure 25. Global Top 5 and 10 Rivaroxaban Players Market Share by Revenue in 2025 Figure 26. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 27. Acute Coronary Syndrome (ACS) Image Figure 28. Global Acute Coronary Syndrome (ACS) Sales YoY Growth (2021-2032) & (M Units) Figure 29. Venous Thromboembolism (VTE) Image Figure 30. Global Venous Thromboembolism (VTE) Sales YoY Growth (2021-2032) & (M Units) Figure 31. Global Rivaroxaban Market Size Overview by Application (2021-2032) & (US$ Million) Figure 32. Global Rivaroxaban Market Share by Application 2025 VS 2032 Figure 33. North America Rivaroxaban Sales Market Share in Volume by Application in 2025 Figure 34. North America Rivaroxaban Sales Market Share in Value by Application in 2025 Figure 35. Europe Rivaroxaban Sales Market Share in Volume by Application in 2025 Figure 36. Europe Rivaroxaban Sales Market Share in Value by Application in 2025 Figure 37. Asia-Pacific Rivaroxaban Sales Market Share in Volume by Application in 2025 Figure 38. Asia-Pacific Rivaroxaban Sales Market Share in Value by Application in 2025 Figure 39. Latin America Rivaroxaban Sales Market Share in Volume by Application in 2025 Figure 40. Latin America Rivaroxaban Sales Market Share in Value by Application in 2025 Figure 41. Middle East and Africa Rivaroxaban Sales Market Share in Volume by Application in 2025 Figure 42. Middle East and Africa Rivaroxaban Sales Market Share in Value by Application in 2025 Figure 43. North America Rivaroxaban Sales by Country: 2021 VS 2025 VS 2032 (M Units) Figure 44. North America Rivaroxaban Sales Share by Country: 2021 VS 2025 VS 2032 Figure 45. North America Rivaroxaban Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 46. North America Rivaroxaban Market Share by Country: 2021 VS 2025 VS 2032 Figure 47. Europe Rivaroxaban Sales by Country: 2021 VS 2025 VS 2032 (M Units) Figure 48. Europe Rivaroxaban Sales Share by Country: 2021 VS 2025 VS 2032 Figure 49. Europe Rivaroxaban Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 50. Europe Rivaroxaban Market Share by Country: 2021 VS 2025 VS 2032 Figure 51. Asia-Pacific Rivaroxaban Sales by Country: 2021 VS 2025 VS 2032 (M Units) Figure 52. Asia-Pacific Rivaroxaban Sales Share by Country: 2021 VS 2025 VS 2032 Figure 53. Asia-Pacific Rivaroxaban Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 54. Asia-Pacific Rivaroxaban Market Share by Country: 2021 VS 2025 VS 2032 Figure 55. Latin America Rivaroxaban Sales by Country: 2021 VS 2025 VS 2032 (M Units) Figure 56. Latin America Rivaroxaban Sales Share by Country: 2021 VS 2025 VS 2032 Figure 57. Latin America Rivaroxaban Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 58. Latin America Rivaroxaban Market Share by Country: 2021 VS 2025 VS 2032 Figure 59. Middle East and Africa Rivaroxaban Sales by Country: 2021 VS 2025 VS 2032 (M Units) Figure 60. Middle East and Africa Rivaroxaban Sales Share by Country: 2021 VS 2025 VS 2032 Figure 61. Middle East and Africa Rivaroxaban Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 62. Middle East and Africa Rivaroxaban Market Share by Country: 2021 VS 2025 VS 2032 Figure 63. Rivaroxaban Value Chain Figure 64. Key Raw Materials Price Figure 65. Manufacturing Cost Structure Figure 66. Rivaroxaban Production Mode & Process Figure 67. Direct Comparison with Distribution Share Figure 68. Distributors Profiles Figure 69. Years Considered Figure 70. Research Process Figure 71. Key Executives Interviewed

Scope & coverage.

Types
  • 2.5 mg
  • 10 mg
  • 15 mg
  • 20 mg
Applications
  • Acute Coronary Syndrome (ACS)
  • Venous Thromboembolism (VTE)
Companies covered
  • Bayer
  • J&J

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Rivaroxaban Market Size Estimates and Forecasts (2021-2032)
  4. 1.2.2 Global Rivaroxaban Sales Estimates and Forecasts (2021-2032)
  5. 1.3 Rivaroxaban Market by Type
  6. 1.3.1 2.5 mg
  7. 1.3.2 10 mg
  8. 1.3.3 15 mg
  9. 1.3.4 20 mg
  10. 1.4 Global Rivaroxaban Market Size by Type
  11. 1.4.1 Global Rivaroxaban Market Size Overview by Type (2021-2032)
  12. 1.4.2 Global Rivaroxaban Historic Market Size Review by Type (2021-2026)
  13. 1.4.3 Global Rivaroxaban Forecasted Market Size by Type (2027-2032)
  14. 1.5 Key Regions Market Size by Type
  15. 1.5.1 North America Rivaroxaban Sales Breakdown by Type (2021-2026)
  16. 1.5.2 Europe Rivaroxaban Sales Breakdown by Type (2021-2026)
  17. 1.5.3 Asia-Pacific Rivaroxaban Sales Breakdown by Type (2021-2026)
  18. 1.5.4 South America Rivaroxaban Sales Breakdown by Type (2021-2026)
  19. 1.5.5 Middle East and Africa Rivaroxaban Sales Breakdown by Type (2021-2026)
2 Global Market Dynamics
  1. 2.1 Rivaroxaban Industry Trends
  2. 2.2 Rivaroxaban Industry Drivers
  3. 2.3 Rivaroxaban Industry Opportunities and Challenges
  4. 2.4 Rivaroxaban Industry Restraints
3 Market Competitive Landscape by Company
  1. 3.1 Global Top Players by Rivaroxaban Revenue (2021-2026)
  2. 3.2 Global Top Players by Rivaroxaban Sales (2021-2026)
  3. 3.3 Global Top Players by Rivaroxaban Price (2021-2026)
  4. 3.4 Global Rivaroxaban Industry Company Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Rivaroxaban Major Company Production Sites & Headquarters
  6. 3.6 Global Rivaroxaban Company, Product Type & Application
  7. 3.7 Global Rivaroxaban Company Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Rivaroxaban Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Rivaroxaban Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Rivaroxaban Tier 1, Tier 2, and Tier 3
4 Rivaroxaban Regional Status and Outlook
  1. 4.1 Global Rivaroxaban Market Size and CAGR by Region: 2021 VS 2025 VS 2032
  2. 4.2 Global Rivaroxaban Historic Market Size by Region
  3. 4.2.1 Global Rivaroxaban Sales in Volume by Region (2021-2026)
  4. 4.2.2 Global Rivaroxaban Sales in Value by Region (2021-2026)
  5. 4.2.3 Global Rivaroxaban Sales (Volume & Value), Price and Gross Margin (2021-2026)
  6. 4.3 Global Rivaroxaban Forecasted Market Size by Region
  7. 4.3.1 Global Rivaroxaban Sales in Volume by Region (2027-2032)
  8. 4.3.2 Global Rivaroxaban Sales in Value by Region (2027-2032)
  9. 4.3.3 Global Rivaroxaban Sales (Volume & Value), Price and Gross Margin (2027-2032)
5 Rivaroxaban by Application
  1. 5.1 Rivaroxaban Market by Application
  2. 5.1.1 Acute Coronary Syndrome (ACS)
  3. 5.1.2 Venous Thromboembolism (VTE)
  4. 5.2 Global Rivaroxaban Market Size by Application
  5. 5.2.1 Global Rivaroxaban Market Size Overview by Application (2021-2032)
  6. 5.2.2 Global Rivaroxaban Historic Market Size Review by Application (2021-2026)
  7. 5.2.3 Global Rivaroxaban Forecasted Market Size by Application (2027-2032)
  8. 5.3 Key Regions Market Size by Application
  9. 5.3.1 North America Rivaroxaban Sales Breakdown by Application (2021-2026)
  10. 5.3.2 Europe Rivaroxaban Sales Breakdown by Application (2021-2026)
  11. 5.3.3 Asia-Pacific Rivaroxaban Sales Breakdown by Application (2021-2026)
  12. 5.3.4 South America Rivaroxaban Sales Breakdown by Application (2021-2026)
  13. 5.3.5 Middle East and Africa Rivaroxaban Sales Breakdown by Application (2021-2026)
6 Company Profiles
  1. 6.1 Bayer
  2. 6.1.1 Bayer Company Information
  3. 6.1.2 Bayer Business Overview
  4. 6.1.3 Bayer Rivaroxaban Sales, Revenue and Gross Margin (2021-2026)
  5. 6.1.4 Bayer Rivaroxaban Product Portfolio
  6. 6.1.5 Bayer Recent Developments
  7. 6.2 J&J
  8. 6.2.1 J&J Company Information
  9. 6.2.2 J&J Business Overview
  10. 6.2.3 J&J Rivaroxaban Sales, Revenue and Gross Margin (2021-2026)
  11. 6.2.4 J&J Rivaroxaban Product Portfolio
  12. 6.2.5 J&J Recent Developments
7 North America by Country
  1. 7.1 North America Rivaroxaban Sales by Country
  2. 7.1.1 North America Rivaroxaban Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 7.1.2 North America Rivaroxaban Sales by Country (2021-2026)
  4. 7.1.3 North America Rivaroxaban Sales Forecast by Country (2027-2032)
  5. 7.2 North America Rivaroxaban Market Size by Country
  6. 7.2.1 North America Rivaroxaban Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 7.2.2 North America Rivaroxaban Market Size by Country (2021-2026)
  8. 7.2.3 North America Rivaroxaban Market Size Forecast by Country (2027-2032)
8 Europe by Country
  1. 8.1 Europe Rivaroxaban Sales by Country
  2. 8.1.1 Europe Rivaroxaban Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 8.1.2 Europe Rivaroxaban Sales by Country (2021-2026)
  4. 8.1.3 Europe Rivaroxaban Sales Forecast by Country (2027-2032)
  5. 8.2 Europe Rivaroxaban Market Size by Country
  6. 8.2.1 Europe Rivaroxaban Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 8.2.2 Europe Rivaroxaban Market Size by Country (2021-2026)
  8. 8.2.3 Europe Rivaroxaban Market Size Forecast by Country (2027-2032)
9 Asia-Pacific by Country
  1. 9.1 Asia-Pacific Rivaroxaban Sales by Country
  2. 9.1.1 Asia-Pacific Rivaroxaban Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 9.1.2 Asia-Pacific Rivaroxaban Sales by Country (2021-2026)
  4. 9.1.3 Asia-Pacific Rivaroxaban Sales Forecast by Country (2027-2032)
  5. 9.2 Asia-Pacific Rivaroxaban Market Size by Country
  6. 9.2.1 Asia-Pacific Rivaroxaban Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 9.2.2 Asia-Pacific Rivaroxaban Market Size by Country (2021-2026)
  8. 9.2.3 Asia-Pacific Rivaroxaban Market Size Forecast by Country (2027-2032)
10 South America by Country
  1. 10.1 South America Rivaroxaban Sales by Country
  2. 10.1.1 South America Rivaroxaban Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 10.1.2 South America Rivaroxaban Sales by Country (2021-2026)
  4. 10.1.3 South America Rivaroxaban Sales Forecast by Country (2027-2032)
  5. 10.2 South America Rivaroxaban Market Size by Country
  6. 10.2.1 South America Rivaroxaban Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 10.2.2 South America Rivaroxaban Market Size by Country (2021-2026)
  8. 10.2.3 South America Rivaroxaban Market Size Forecast by Country (2027-2032)
11 Middle East and Africa by Country
  1. 11.1 Middle East and Africa Rivaroxaban Sales by Country
  2. 11.1.1 Middle East and Africa Rivaroxaban Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 11.1.2 Middle East and Africa Rivaroxaban Sales by Country (2021-2026)
  4. 11.1.3 Middle East and Africa Rivaroxaban Sales Forecast by Country (2027-2032)
  5. 11.2 Middle East and Africa Rivaroxaban Market Size by Country
  6. 11.2.1 Middle East and Africa Rivaroxaban Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 11.2.2 Middle East and Africa Rivaroxaban Market Size by Country (2021-2026)
  8. 11.2.3 Middle East and Africa Rivaroxaban Market Size Forecast by Country (2027-2032)
12 Value Chain and Sales Channels Analysis
  1. 12.1 Rivaroxaban Value Chain Analysis
  2. 12.1.1 Rivaroxaban Key Raw Materials
  3. 12.1.2 Key Raw Materials Price
  4. 12.1.3 Raw Materials Key Suppliers
  5. 12.1.4 Manufacturing Cost Structure
  6. 12.1.5 Rivaroxaban Production Mode & Process
  7. 12.2 Rivaroxaban Sales Channels Analysis
  8. 12.2.1 Direct Comparison with Distribution Share
  9. 12.2.2 Rivaroxaban Distributors
  10. 12.2.3 Rivaroxaban Customers
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources
    8. 14.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,450USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst